「NSAIDs」の共起表現一覧(1語右で並び替え)
該当件数 : 39件
| west cost treatment was celecoxib, followed by | NSAIDs alone and diclofenac/misoprostol, with the oth |
| d cost effectiveness of celecoxib, nonspecific | NSAIDs alone, NSAIDs plus a proton pump inhibitor, NS |
| Fever and pain should be controlled by giving | NSAIDs, analgetics or antipyretics before application |
| Both | NSAIDs and Coxibs can raise the risk of myocardial in |
| (urticaria or anaphylaxis) to aspirin or other | NSAIDs, and should be used with caution by persons ha |
| position 7 have the potential to interact with | NSAIDs and/or their metabolites, resulting in antagon |
| hat glucosamine, unlike pain relievers such as | NSAIDs, can actually help prevent the destruction of |
| include nonsteroidal anti-inflammatory drugs ( | NSAIDs), colchicine and steroids, while options for p |
| s are needed to dilate the afferent arteriole; | NSAIDs effectively reverse this.) |
| vely less irritating to the stomach than other | NSAIDs except for drugs of the COX-2 inhibitor class. |
| As with other | NSAIDs, fluid and solute retention and edema have bee |
| NSAIDs have some mild GABA antagonistic properties an | |
| ost other nonsteroidal antiinflammatory drugs ( | NSAIDs) including ibuprofen and naprosyn. |
| NSAIDs inhibit cyclooxygenase and reduce prostaglandi | |
| NSAIDs inhibit the formation of such inflammatory sub | |
| he activity of paracetamol, aspirin, and other | NSAIDs, it has been postulated that further COX varia |
| Like most | NSAIDs, it can produce gastrointestinal (GI) side eff |
| Unlike other | NSAIDs, it does not inhibit cyclooxygenase or lipooxy |
| Like other | NSAIDs, it is useful in the treatment of acute or chr |
| Similar to classical | NSAIDs, it is a non-selective inhibitor of cyclooxyge |
| erties comparable to those of aspirin or other | NSAIDs, its peripheral anti-inflammatory activity is |
| As with all | NSAIDs, ketorolac should be avoided in patients with |
| With | NSAIDs like Salicylates, Sulphonamides, Chloramphenic |
| Patients have reported reactions to | NSAIDS long after completion of fluoroquinolone thera |
| Like all | NSAIDs on the U.S. market, celecoxib carries an FDA-m |
| indicated in patients that must not take other | NSAIDs, possible reasons including salicylate sensiti |
| NSAIDs should be discontinued prior to elective surge | |
| Others include | NSAIDs, St. John's wort, and aspirin. |
| s of NSAID drugs, particularly COX-2 selective | NSAIDs such as celecoxib, since the withdrawal of the |
| paracetamol (acetaminophen), or certain older | NSAIDs, such as naproxen, may be safer choices for ch |
| ructure to non-steroidal antinflammtory drugs ( | NSAIDs) such as indometacin. |
| effects were observed with similar efficacy to | NSAIDs such as naproxen or diclofenac, and anti-allod |
| However, | NSAIDs taken in combination with fluoroquinolones cau |
| thma, Pediatrics, CNS, GI, Anti-Infectives and | NSAIDs therapy and world largest manufacturer of Anti |
| lease formulations or chemical modification of | NSAIDs to form prodrugs has been suggested as a metho |
| Sulindac is much more likely than other | NSAIDs to cause damage to the liver or pancreas. |
| Ranitidine can also be co-administered with | NSAIDs to reduce the risk of ulceration. |
| A study from 2010 has shown regular use of | NSAIDs was associated with an increase in hearing los |
| he cardiovascular risks of celecoxib and other | NSAIDs were meta-analyses, published in 2006. |
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|
こんにちは ゲスト さん
|
ログイン |
Weblio会員(無料)になると
|